• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Morphic Holding Inc.

    8/16/24 4:07:51 PM ET
    $MORF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MORF alert in real time by email
    8-K
    false 0001679363 --12-31 0001679363 2024-08-16 2024-08-16

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 16, 2024

     

     

    Morphic Holding, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-38940   47-3878772

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    35 Gatehouse Drive, A2  
    Waltham, Massachusetts   02451
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (781) 996-0955

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.0001 par value per share   MORF   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Introductory Note

    As previously disclosed in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 8, 2024 (the “Announcement Report”), Morphic Holding, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of July 7, 2024, by and among the Company, Eli Lilly and Company, an Indiana corporation (“Parent”), and Rainier Acquisition Corporation, a Delaware corporation (“Purchaser”) and wholly owned subsidiary of Parent.

    Pursuant to the Merger Agreement, on July 19, 2024, Purchaser commenced a tender offer (the “Offer”) to purchase all of the issued and outstanding shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $57.00 per Share (the “Offer Price”), net to the stockholder in cash, without interest thereon and subject to any applicable tax withholding.

    The Offer and related withdrawal rights expired as scheduled at one minute past 11:59 p.m., Eastern Time, on August 15, 2024 (such date and time, the “Expiration Time”), and was not further extended. Computershare Trust Company, N.A., in its capacity as depositary and paying agent for the Offer (the “Depositary and Paying Agent”), has advised Purchaser that, as of the Expiration Time, 46,731,511 Shares had been validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 92.8% of the issued and outstanding Shares as of the Expiration Time. Accordingly, the Minimum Tender Condition (as defined in the Merger Agreement) has been satisfied. As a result of the satisfaction of the Minimum Tender Condition and each of the other conditions to the Offer, on August 16, 2024, Parent and Purchaser accepted for payment the Shares that were validly tendered and not validly withdrawn pursuant to the Offer prior to the Expiration Time. Parent has transmitted payment for such Shares to the Depositary and Paying Agent, which will disburse the Offer Price to tendering Company stockholders whose Shares have been accepted for payment in accordance with the terms of the Offer.

    Following the consummation of the Offer, pursuant to the terms and subject to the conditions of the Merger Agreement, in accordance with Section 251(h) of the General Corporation Law of the State of Delaware (the “DGCL”) and without a meeting or a vote of the Company’s stockholders, on August 16, 2024, Purchaser was merged with and into the Company (the “Merger”), with the Company continuing as the surviving corporation and becoming a wholly owned subsidiary of Parent.

    Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger (the “Effective Time”), by virtue of the Merger and without any action on the part of the holders thereof, each Share issued and outstanding immediately prior to the Effective Time (other than (i) Shares owned by the Company or any wholly owned subsidiary of the Company immediately prior to the Effective Time, (ii) Shares owned by Parent, Purchaser or any other subsidiary of Parent or Purchaser at the commencement of the Offer and owned by Parent, Purchaser or any other subsidiary of Parent immediately prior to the Effective Time, (iii) Shares irrevocably accepted for purchase in the Offer or (iv) Shares that were held by stockholders who were entitled to demand and properly demanded appraisal for such Shares pursuant to and in compliance in all respects with Section 262 of the DGCL and did not fail to perfect or otherwise waive, withdraw or lose their rights to such appraisal with respect to such Shares under the DGCL), was automatically converted into the right to receive the Offer Price in cash and without interest, from Purchaser, subject to any applicable tax withholding.

    Pursuant to the Merger Agreement, the treatment of the Company’s equity awards was as follows:

     

    •  

    Immediately prior to the Effective Time, each stock option to purchase Common Stock of the Company that was outstanding but not then vested or exercisable was immediately vested and became exercisable in full. At the Effective Time, each outstanding stock option granted under a Company Stock Plan (as defined in the Merger Agreement) that had an exercise price per Share less than the Offer Price was canceled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the number of Shares underlying such stock option and (ii) the excess, if any, of the Offer Price over the exercise price per Share underlying such stock option. Any stock options that had an exercise price per Share that equaled or exceeded the Offer Price were canceled for no consideration; and

     


    •  

    Immediately prior to the Effective Time, each Company restricted stock unit that was outstanding but not then vested became immediately vested in full. At the Effective Time, each outstanding restricted stock unit of the Company was canceled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of Shares underlying such restricted stock unit.

    The foregoing description of the Offer, the Merger and the Merger Agreement is subject to, and qualified in its entirety by, the full text of the Merger Agreement, a copy of which was filed as Exhibit 2.1 to the Announcement Report and is incorporated herein by reference.

     

    Item 1.02

    Termination of a Material Definitive Agreement.

    On August 16, 2024, in connection with the consummation of the Merger and effective as of the Effective Time, (i) the Company terminated the Company’s 2018 Stock Incentive Plan, Amended and Restated 2019 Equity Incentive Plan, 2019 Employee Stock Purchase Plan and 2024 Equity Inducement Plan and (ii) the Investors’ Rights Agreement entered into as of December 5, 2018, by and among the Company and the investors listed on Schedule A thereto, terminated automatically in accordance with its terms.

    In addition, as previously disclosed, on April 26, 2024, the Company entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (the “Sales Agent”) with respect to an “at-the-market” offering program, under which the Company could offer and sell, from time to time, shares of its Common Stock through the Sales Agent. Effective as of August 16, 2024, the Company terminated the Sales Agreement.

     

    Item 2.01

    Completion of Acquisition or Disposition of Assets.

    The information contained in the Introductory Note of this Current Report on Form 8-K is incorporated herein by reference.

     

    Item 3.01

    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    On August 16, 2024, the Company (i) notified The Nasdaq Global Market (“Nasdaq”) of the consummation of the Merger and (ii) requested that Nasdaq suspend trading of the Common Stock, effective as of close of business on August 16, 2024, and file with the SEC a Form 25, Notification of Removal from Listing and/or Registration, to delist all the Common Stock from Nasdaq and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company also intends to file a Certification and Notice of Termination of Registration on Form 15 with the SEC requesting the termination of registration of the Common Stock under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.

     

    Item 3.03

    Material Modification to Rights of Security Holders.

    The information set forth in the Introductory Note and Items 2.01, 3.01 and 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

     

    Item 5.01

    Change in Control of Registrant.

    The information contained in the Introductory Note and Items 2.01, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

    As a result of the consummation of the Offer and the consummation of the Merger in accordance with Section 251(h) of the DGCL on August 16, 2024, a change in control of the Company occurred. At the Effective Time, the Company became a wholly owned subsidiary of Parent. The Offer Price was funded with the net proceeds from a debt issuance by Parent.

     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    The information set forth in the Introductory Note of this Current Report on Form 8-K is incorporated herein by reference.

    In accordance with the terms of the Merger Agreement, (i) each of Gustav Christensen, Timothy A. Springer, Ph.D., Norbert Bischofberger, Ph.D., Martin Edwards, Susannah Gray, Nisha Nanda, Ph.D, Amir Nashat, Sc.D., Joseph P. Slattery, and Praveen P. Tipirneni, M.D. resigned from his or her respective position as a member of the Company’s board of directors and all committees thereof, effective as of the Effective Time and (ii) Gordon J. Brooks, Michael C. Thompson and Christopher Anderson, each a director of Purchaser immediately prior to the Effective Time, became directors of the Company, in each case, effective as of the Effective Time. The resignations described in clause (i) of the preceding sentence were tendered in connection with the Merger and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company’s operations, policies or practices.

    In accordance with the terms of the Merger Agreement, each officer of Purchaser immediately prior to the Effective Time became an officer of the Company effective as of the Effective Time. The officers of Purchaser immediately prior to the Effective Time were Michael C. Thompson as President and Treasurer, Christopher Anderson as Secretary, Katie Lodato as Assistant Treasurer and Jonathan Groff as Assistant Secretary. Effective immediately following completion of the Merger, all of the incumbent officers of the Company as of immediately prior to the Effective Time were removed as officers of the Company.

    Biographical and other information with respect to Gordon J. Brooks, Michael C. Thompson, Christopher Anderson, Katie Lodato and Jonathan Groff is set forth in Schedule I to the Offer to Purchase, a copy of which is attached as Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO filed with the SEC by Parent on July 19, 2024 and is incorporated herein by reference.

     

    Item 5.03

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    Pursuant to the terms of the Merger Agreement, the restated certificate of incorporation of the Company was amended and restated in its entirety, effective as of the Effective Time, and the bylaws of the Purchaser became the bylaws of the Company, effective as of immediately following the Effective Time. Copies of the Company’s amended and restated certificate of incorporation and amended and restated bylaws are included as Exhibits 3.1 and 3.2 hereto, respectively, and are incorporated by reference herein.

     

    Item 9.01

    Financial Statements and Exhibits.

     

    (d)

    Exhibits

     

    Exhibit
    No.
      

    Description

    2.1    Agreement and Plan of Merger, dated July 7, 2024, by and among Eli Lilly and Company, Rainier Acquisition Corporation and Morphic Holding, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Morphic Holding, Inc. with the Securities and Exchange Commission on July 8, 2024 (File No. 001- 38940)). *
    3.1    Amended and Restated Certificate of Incorporation of Morphic Holding, Inc. **
    3.2    Amended and Restated Bylaws of Morphic Holding, Inc. **
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    *

    Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished supplementally to the SEC upon request.

    **

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      MORPHIC HOLDING, INC.
    Date: August 16, 2024   By:  

    /s/ Michael C. Thompson

      Name:   Michael C. Thompson
      Title:   President
    Get the next $MORF alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MORF

    DatePrice TargetRatingAnalyst
    12/8/2023$46.00Buy
    Citigroup
    9/25/2023$61.00 → $33.00Hold
    Stifel
    9/25/2023Buy → Neutral
    BTIG Research
    8/9/2023$69.00 → $61.00Buy → Hold
    Stifel
    9/7/2022$44.00Buy
    Stifel
    7/20/2022$45.00Outperform
    SVB Leerink
    3/31/2022$68.00Buy
    Canaccord Genuity
    2/25/2022$82.00 → $76.00Outperform
    RBC Capital
    More analyst ratings

    $MORF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Morphic with a new price target

      Citigroup initiated coverage of Morphic with a rating of Buy and set a new price target of $46.00

      12/8/23 7:51:26 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Morphic with a new price target

      Stifel reiterated coverage of Morphic with a rating of Hold and set a new price target of $33.00 from $61.00 previously

      9/25/23 11:48:40 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic downgraded by BTIG Research

      BTIG Research downgraded Morphic from Buy to Neutral

      9/25/23 7:17:39 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Edwards Martin returned 2,376 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/21/24 4:36:17 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Slattery Joseph P returned 9,066 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/20/24 7:12:13 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Nashat Amir closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/20/24 7:11:28 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Edwards Martin bought $48,803 worth of shares (2,376 units at $20.54) (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      11/15/23 7:00:10 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Slattery Joseph P bought $49,436 worth of shares (2,400 units at $20.60), increasing direct ownership by 36% to 9,066 units (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      11/14/23 7:04:11 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Financials

    Live finance-specific insights

    See more
    • Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

      Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i

      8/16/24 8:38:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023

      -Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027- WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter 2023. "Morphic presented a compre

      11/3/23 7:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set

      WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The positive topline results from EMERALD-1 were reported in April of this year and the full data set will be presented at the upcoming UEG Week 2023. The webcast and call will be held at 7:45 AM Eastern Time on October 12, 2023. A live webcast of the call will be available via

      10/9/23 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      8/12/24 9:40:06 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      8/7/24 7:47:40 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      7/8/24 10:07:20 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    SEC Filings

    See more
    • SEC Form 15-12G filed by Morphic Holding Inc.

      15-12G - Morphic Holding, Inc. (0001679363) (Filer)

      8/26/24 7:39:57 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Morphic Holding Inc.

      S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)

      8/16/24 4:27:56 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Morphic Holding Inc.

      S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)

      8/16/24 4:25:26 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

      Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing

      7/21/25 7:00:00 AM ET
      $BBNX
      $BCAX
      $KMTS
      $MORF
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

      Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i

      8/16/24 8:38:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

      Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Morphic Holding, Inc. (NASDAQ:MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. Morphic's lead program is a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD) that has the potential to improve outcomes and expand treatment options for patients. This molecule (known as MORF-057) is being evaluated in two Phase 2 studies in ulcera

      7/8/24 6:45:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Leadership Updates

    Live Leadership Updates

    See more
    • Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

      WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a proven history across all phases of clinical development and in a wide variety of therapeutic areas, particularly autoimmune, inflammatory, cardiovascular, and pulmonary diseases. Dr. Cooper most recently served as Chief Medical Officer of Keros Therapeutics. "Simon brings clinical development expe

      3/19/24 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022

      -Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- -Launched EMERALD-2 phase 2b global randomized trial of MORF-057 in ulcerative colitis- -Ended 2022 with $348 million in cash and equivalents; ~$100 million from February private placement extends cash runway into second half of 2026 WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2022. 2022 and Recent Corporate H

      2/23/23 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

      WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Joanne Gibbons has been named Senior Vice President of Regulatory Affairs. Ms. Gibbons was previously Vice President and Head of Regulatory Affairs at Codiak Biosciences. "Joanne arrives at Morphic at a promising time. We are advancing clinical and pre-clinical integrin inhibitors generated by the MInT Platform and Joanne brings successful leadership experience across the full spectrum of regulatory affairs from preclinical activities through drug commer

      5/18/22 7:30:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care